Yiou Healthcare News on May 6: Recently, VIVAVISION announced the completion of over 100 million yuan in D2 round financing. This round of financing was led byV Capital Co., Ltd., Shengze Investment (Shanghai) Co., Ltd., Zhejiang Shengyuan Zhiben Asset Management Co., Ltd., and VVB Fundand other institutions jointly completed. Currently, the company is fully advancing the commercial cooperation of its mid-to-late stage pipeline and industrial layout. The proceeds from this round of financing will be mainly used forMultiple Clinical Trials of Ophthalmic Innovative DrugsAdvance, preclinical pipeline R&D, and technology innovation platform expansion.
VIVAVISION was founded in August 2016 and is aFocus on the Field of Ophthalmic Innovative Drug Research and DevelopmentA clinical-stage biotechnology company with a professional ophthalmic innovative drug R&D team and technology platform. The company has established a series of product pipelines through independent research and development, among which three products have entered the clinical stage, respectively:VVN001 for the treatment of dry eye, VVN539, a dual-target small molecule drug for the treatment of glaucoma, and VVN461 for the treatment of non-infectious anterior uveitis, postoperative inflammation, etc.。
In addition to covering ocular surface diseases, VIVAVISION has also established a pipeline and technology platform for retinal diseases. This includes a sustained-release pipeline for posterior/pan-uveitis and a bispecific antibody pipeline for treating diabetic macular edema and diabetic retinopathy. Relevant research and clinical registration applications are currently being actively advanced.